A
AgilentDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
Current thesis
Q1 company results were constructive: Agilent reported 4.4% core growth and raised FY2026 revenue and EPS guidance, which leaves room for the stock to rerate if Q2 confirms that momentum and the Biocare deal closes on time [#IR-2026-02-25][#PR-2026-03-09].
Posture
Defensive
Lead driver
Value
What changed
254 setup hits (3d) with net bullish as of 2026-07-17.
What can break
Biocare still needs regulatory approvals and integration execution, and EPS accretion is not expected until roughly 12 months after close [#PR-2026-03-09].
Momentum
34
Value
62
Sentiment
32
Setup hits (3d)
254 · Net Bullish
AI TargetsBase $116.00 · Bull $132.00 · Bear $96.00
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $159.33
Why
Momentum34 · Δ7d -26.3
Value62 · Δ7d -0.0
Sentiment32 · Δ7d -5.7
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
34
26% active weight
Current posture
7d trendFlat
Δ7d
-26.3
Δ21d
-41.2
Value
62
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
32
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.7
Δ21d
-1.2
Why this grade
Composite grade D. Momentum 34.4 / Value 61.7 / Sentiment 32.2
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$37.13B
Beta
1.30
Shares Out
282.43M
P/E (TTM)
31.3
P/S (TTM)
5.83
P/FCF (TTM)
46.58
Rev YoY
+10.0%
EPS YoY
+58.8%
Gross Margin
+52.8%
Op Margin
+21.3%
Net Debt
$1.75B
Current Ratio
2.10
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology